Drug firm Suven Life Sciences has received one product patent each from Australia and the US for its molecule to be used in the treatment of neuro- degenerative diseases. These patents are valid through 2032 and 2034, respectively, the drug maker said in a filing to the BSE. These patents have been granted for Suven’s pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally, CEO Venkat Jasti said.
The molecules are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, Suven Life Sciences said.
The stock traded at Rs 187.65 on the BSE, up 1.73 per cent from its previous close.